For months, commentary on Boehringer has flourished across the European patent community. Yet amid the noise, the fundamental question—what the decision truly changes in the logic of injunctions—…
After two years, the UPC's track record concerning its decisions has been rather good so far. Although, of course, in each specific case one of the parties will disagree with the decision, the…
At the AIPPI, irony sometimes writes itself. In 2020, when the Association launched its essay competition, I submitted a paper on compulsory licenses and legitimacy — optimistically entitled “COVID-…
In late September, the Mannheim Local Division of the Unified Patent Court (UPC) and Germany’s Munich Regional Court issued the world’s first “anti-interim license” injunction orders (AILIs). These…
German patent law as a system of reasonI had the chance to receive, ahead of publication, a copy of Pharmaceutical, Biological and Chemical Patents by Marco Stief, Maximilian Haedicke, and Annelie…
AI is driving innovation in every single industry. Particularly health care is facing unprecedented automation in its ecosystem from care management to real time inputs from medical literature. The…
Coinciding with the 100th year anniversary of the German and UK national groups of AIPPI, the GRUR Annual Meeting in Berlin hosted an “AIPPI Special” on 16 October 2025 to discuss the state of play…
The basic patent and SPC on Stelara®, the successful blockbuster drug of Janssen, have expired, which means that the generic producer Samsung Bioepis can potentially bring its generic drug on the…
Remember the days of old? The burning days of Brexit. When the UK decided to withdraw from the EU and the UPC system. When UK Judges would not become UPC judges. When Milan replaced London as a…
Preliminary injunctions (“PIs”) matter in life sciences patent cases. As often as not, the party which prevails at this stage of the litigation will have the upper hand in settlement…
